Valuation: Axsome Therapeutics, Inc.

Market Cap 10.22B 8.97B 8.47B 7.72B 14.45B 979B 14.55B 101B 39.25B 500B 38.37B 37.54B 1,608B P/E 2026 *
-72.6x
P/E 2027 * 43.9x
Enterprise Value 10.07B 8.83B 8.34B 7.6B 14.23B 965B 14.33B 99.83B 38.66B 493B 37.79B 36.98B 1,584B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.32x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week-6.11%
Current month-1.73%
1 month-5.06%
3 months-17.80%
6 months+20.59%
Current year+6.82%
1 week 189.05
Extreme 189.05
210.85
1 month 189.05
Extreme 189.05
229.62
Current year 152.28
Extreme 152.28
260.19
1 year 116.18
Extreme 116.1756
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Exercice

Chief Operating Officer

30,000 0.0573%
8/6/26 Exercice

Chief Executive Officer

13,980 0.0272%
7/1/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-6.11%+68.17%+175.82% 10.22B
-1.00%+0.41%+41.86%-5.58% 78.69B
+2.08%+29.11%+708.13%+102.59% 79.4B
-1.21%+0.77%-10.63%-30.06% 59.52B
-1.80%-2.29%-13.07%+28.02% 46.53B
+1.18%+3.03%+9.11%+169.01% 46.58B
+0.55%+5.61%+67.76%-10.75% 33.63B
-0.44%-1.13%+51.71%+110.88% 25.11B
-0.10%+3.21%+4.89%+155.64% 22.13B
+0.05%-2.42%+57.59%+97.38% 15.31B
Average -0.37%+3.03%+98.55%+79.29% 41.71B
Weighted average by Cap. -0.51%+6.14%+153.36%+58.13%

Financials

2026 *2027 *
Net sales 964M 846M 799M 728M 1.36B 92.43B 1.37B 9.56B 3.7B 47.22B 3.62B 3.54B 152B 1.55B 1.36B 1.28B 1.17B 2.19B 148B 2.2B 15.35B 5.95B 75.78B 5.81B 5.69B 244B
Net income -141M -124M -117M -107M -200M -13.53B -201M -1.4B -542M -6.91B -530M -519M -22.22B 245M 215M 203M 185M 346M 23.44B 348M 2.43B 940M 11.98B 918M 899M 38.49B
Net Debt -153M -134M -127M -116M -217M -14.68B -218M -1.52B -588M -7.5B -575M -563M -24.11B -430M -377M -356M -325M -608M -41.23B -612M -4.27B -1.65B -21.06B -1.61B -1.58B -67.69B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-09-25 US$195.09 -0.48% 838,181
26-09-24 US$196.03 +1.33% 386,176
26-09-23 US$193.45 -4.75% 912,995
26-09-22 US$203.10 -1.16% 299,785
26-09-21 US$205.49 -1.10% 543,471
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
195.09USD
Average target price
285.22USD
Spread / Average Target
+46.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock